Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Escherichia coli O157:H7 ATP-dependent protease ATPase subunit HslU (hslU) CSB-YP475586EOE
CSB-EP475586EOE
CSB-BP475586EOE
CSB-MP475586EOE
CSB-EP475586EOE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 Ribosomal RNA small subunit methyltransferase H (rsmH) CSB-YP475587EOE
CSB-EP475587EOE
CSB-BP475587EOE
CSB-MP475587EOE
CSB-EP475587EOE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 DNA gyrase inhibitor YacG (yacG) CSB-YP475588EOE
CSB-EP475588EOE
CSB-BP475588EOE
CSB-MP475588EOE
CSB-EP475588EOE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 3-methyl-2-oxobutanoate hydroxymethyltransferase (panB) CSB-YP475589EOE
CSB-EP475589EOE
CSB-BP475589EOE
CSB-MP475589EOE
CSB-EP475589EOE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 Cell division protein ZipA homolog (zipA), partial CSB-YP475590EOE
CSB-EP475590EOE
CSB-BP475590EOE
CSB-MP475590EOE
CSB-EP475590EOE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 Phosphoribosylformylglycinamidine cyclo-ligase (purM) CSB-YP475591EOE
CSB-EP475591EOE
CSB-BP475591EOE
CSB-MP475591EOE
CSB-EP475591EOE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 50S ribosomal protein L11 (rplK) CSB-YP475592EOE
CSB-EP475592EOE
CSB-BP475592EOE
CSB-MP475592EOE
CSB-EP475592EOE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 Thiamine-phosphate synthase (thiE) CSB-YP475593EOE
CSB-EP475593EOE
CSB-BP475593EOE
CSB-MP475593EOE
CSB-EP475593EOE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 Glutamate-1-semialdehyde 2,1-aminomutase (hemL) CSB-YP475594EOE
CSB-EP475594EOE
CSB-BP475594EOE
CSB-MP475594EOE
CSB-EP475594EOE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 UPF0325 protein yaeH (yaeH) CSB-YP475595EOE
CSB-EP475595EOE
CSB-BP475595EOE
CSB-MP475595EOE
CSB-EP475595EOE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 (3R)-hydroxymyristoyl-[acyl-carrier-protein] dehydratase CSB-YP475596EOE
CSB-EP475596EOE
CSB-BP475596EOE
CSB-MP475596EOE
CSB-EP475596EOE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 Proline--tRNA ligase (proS) CSB-YP475597EOE
CSB-EP475597EOE
CSB-BP475597EOE
CSB-MP475597EOE
CSB-EP475597EOE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 Zinc transport protein ZntB (zntB), partial CSB-YP475598EOE1
CSB-EP475598EOE1
CSB-BP475598EOE1
CSB-MP475598EOE1
CSB-EP475598EOE1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 Peptidase B (pepB) CSB-YP475599EOE
CSB-EP475599EOE
CSB-BP475599EOE
CSB-MP475599EOE
CSB-EP475599EOE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 4-hydroxybenzoate octaprenyltransferase (ubiA), partial CSB-YP475600EOE1
CSB-EP475600EOE1
CSB-BP475600EOE1
CSB-MP475600EOE1
CSB-EP475600EOE1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 Gamma-glutamyl phosphate reductase (proA) CSB-YP475601EOE
CSB-EP475601EOE
CSB-BP475601EOE
CSB-MP475601EOE
CSB-EP475601EOE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 Betaine aldehyde dehydrogenase (betB) CSB-YP475602EOE
CSB-EP475602EOE
CSB-BP475602EOE
CSB-MP475602EOE
CSB-EP475602EOE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 Probable sugar efflux transporter (sotB), partial CSB-YP475603EOE
CSB-EP475603EOE
CSB-BP475603EOE
CSB-MP475603EOE
CSB-EP475603EOE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 10 kDa chaperonin (groS) CSB-YP475604EOE
CSB-EP475604EOE
CSB-BP475604EOE
CSB-MP475604EOE
CSB-EP475604EOE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O157:H7 Probable L-ascorbate-6-phosphate lactonase ulaG (ulaG) CSB-YP475605EOE
CSB-EP475605EOE
CSB-BP475605EOE
CSB-MP475605EOE
CSB-EP475605EOE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>